Genelux Corporation (GNLX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$2.48+$0.0500 (+2.06%) on the dayAs of the close; data may be delayed.
GNLX price, last 12 months
Key stats
- Previous close
- $2.43
- Open
- $2.47
- Day range
- $2.42 – $2.54
- 52-week range
- $2.29 – $8.54
- Volume
- 139.9K
- Avg volume (20 days)
- 274K
- Market cap
- $112.2M
Performance
1W−2.0%
1M−9.2%
3M−13.6%
6M−5.7%
YTD−43.1%
1Y−43.3%
vs S&P 500, 1Y−60.0 pts
Technicals and fundamentals
About Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $112.2M